Jessica L Mellinger1, Gerald Scott Winder2, Anne C Fernandez3, Kristin Klevering4, Amanda Johnson5, Haila Asefah5, Mary Figueroa6, Jack Buchanan7, Fred Blow3, Anna S F Lok5. 1. Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, United States of America. Electronic address: jmelling@med.umich.edu. 2. Department of Psychiatry, Michigan Medicine, Ann Arbor, MI, United States of America; Department of Surgery, Michigan Medicine, Ann Arbor, MI, United States of America. 3. Department of Psychiatry, Michigan Medicine, Ann Arbor, MI, United States of America; University of Michigan Addiction Treatment Service, Michigan Medicine, Ann Arbor, MI, United States of America. 4. University of Michigan Addiction Treatment Service, Michigan Medicine, Ann Arbor, MI, United States of America; Department of Social Work, Michigan Medicine, Ann Arbor, MI, United States of America. 5. Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, United States of America. 6. School of Public Health, University of Michigan, Ann Arbor, MI, United States of America. 7. University of Michigan Medical School, Ann Arbor, MI, United States of America.
Abstract
BACKGROUND: Alcohol cessation improves mortality in alcohol-associated liver disease (ALD), but access to treatment is limited. To address this gap, implementation and early feasibility and outcomes of a multidisciplinary ALD clinic are described. METHODS: The clinic comprised a hepatologist, psychiatrist, psychologist, nurse, and social worker. Patients included those with alcohol-associated cirrhosis or acute alcoholic hepatitis who were not in the transplant evaluation process, who had less than 6 months' sobriety and willingness to engage in alcohol use treatment. Psychosocial metrics in addition to routine hepatic function labs were collected. Treatment plans were tailored based on patient preferences and needs after multidisciplinary discussion. RESULTS: 89 patients were referred from both inpatient and outpatient settings, with 51 seen during the initial year. 38 remained active in clinic (4 died, 6 discharged, 3 moved to transplant clinic). 55% were women, 88% were white, 61% had private insurance. 49% had alcoholic hepatitis. 71% were decompensated. 80% had severe alcohol use disorder (AUD) and 84% had at least 1 comorbid psychiatric or substance use disorder. 63% chose one-on-one AUD treatment, 57% were prescribed relapse prevention medications. Mean MELD-Na score improved from baseline of 14 (SD 6.6) to 11.3 at 6 months (p=0.01). Hospital utilization significantly declined when comparing 6 months before to 6 months after initial visit (emergency department visits: 0.51 to 0.20 per person-month; inpatient admission: 0.34 to 0.14 per person-month; (β= -0.89, 95% CI -1.18 to -0.60). CONCLUSIONS: A multidisciplinary ALD clinic was feasible with encouraging early outcomes. Further research should explore ways to expand this model and increase clinic capacity.
BACKGROUND: Alcohol cessation improves mortality in alcohol-associated liver disease (ALD), but access to treatment is limited. To address this gap, implementation and early feasibility and outcomes of a multidisciplinary ALD clinic are described. METHODS: The clinic comprised a hepatologist, psychiatrist, psychologist, nurse, and social worker. Patients included those with alcohol-associated cirrhosis or acute alcoholic hepatitis who were not in the transplant evaluation process, who had less than 6 months' sobriety and willingness to engage in alcohol use treatment. Psychosocial metrics in addition to routine hepatic function labs were collected. Treatment plans were tailored based on patient preferences and needs after multidisciplinary discussion. RESULTS: 89 patients were referred from both inpatient and outpatient settings, with 51 seen during the initial year. 38 remained active in clinic (4 died, 6 discharged, 3 moved to transplant clinic). 55% were women, 88% were white, 61% had private insurance. 49% had alcoholic hepatitis. 71% were decompensated. 80% had severe alcohol use disorder (AUD) and 84% had at least 1 comorbid psychiatric or substance use disorder. 63% chose one-on-one AUD treatment, 57% were prescribed relapse prevention medications. Mean MELD-Na score improved from baseline of 14 (SD 6.6) to 11.3 at 6 months (p=0.01). Hospital utilization significantly declined when comparing 6 months before to 6 months after initial visit (emergency department visits: 0.51 to 0.20 per person-month; inpatient admission: 0.34 to 0.14 per person-month; (β= -0.89, 95% CI -1.18 to -0.60). CONCLUSIONS: A multidisciplinary ALD clinic was feasible with encouraging early outcomes. Further research should explore ways to expand this model and increase clinic capacity.
Authors: Anam Khan; Aylin Tansel; Donna L White; Waleed Tallat Kayani; Shah Bano; Jan Lindsay; Hashem B El-Serag; Fasiha Kanwal Journal: Clin Gastroenterol Hepatol Date: 2015-08-06 Impact factor: 11.382
Authors: Fasiha Kanwal; Elliot B Tapper; Chanda Ho; Sumeet K Asrani; Nadia Ovchinsky; John Poterucha; Avegail Flores; Victor Ankoma-Sey; Bruce Luxon; Michael Volk Journal: Hepatology Date: 2019-03-12 Impact factor: 17.425
Authors: Jessica L Mellinger; Kerby Shedden; Gerald Scott Winder; Elliot Tapper; Megan Adams; Robert J Fontana; Michael L Volk; Frederic C Blow; Anna S F Lok Journal: Hepatology Date: 2018-05-20 Impact factor: 17.425
Authors: Jessica L Mellinger; Anne Fernandez; Kerby Shedden; G Scott Winder; Robert J Fontana; Michael L Volk; Frederic C Blow; Anna S F Lok Journal: Alcohol Clin Exp Res Date: 2019-01-22 Impact factor: 3.455
Authors: Nneka N Ufere; Jan Hinson; Simon Finnigan; Elizabeth E Powell; John Donlan; Cathy Martin; Phil Clark; Patricia C Valery Journal: Curr Treat Options Gastroenterol Date: 2022-04-19
Authors: Juan Pablo Arab; Manhal Izzy; Lorenzo Leggio; Ramon Bataller; Vijay H Shah Journal: Nat Rev Gastroenterol Hepatol Date: 2021-11-01 Impact factor: 73.082